Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27774480 | 0.85 | MEN1 (0.53) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL27578920 | 0.84 | MEN1 (0.51) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL2493638 | 0.84 | MEN1 (0.51) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL27766267 | 0.83 | KMT2A (0.50) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL6189602 | 0.80 | KMT2A (0.47) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL12084861 | 0.80 | RAB9A (0.48) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL12928357 | 0.80 | MEN1 (0.81) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL27969685 | 0.79 | GAA (0.61) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL15343541 | 0.78 | MEN1 (0.56) | KMT2AMEN1RAB9AFAAHBCHE | |
| SCHEMBL28868300 | 0.77 | MEN1 (0.44) | KMT2AMEN1RAB9ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8258148-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7786141-B2 | Dihydrospiroindene modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM4 | KMT2A 1874/4885MEN1 2541/4885RAB9A 2617/4885 |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | CHRM3, CHRM5, CHRM2 | KMT2A 2362/4885MEN1 2672/4885RAB9A 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.